每经AI快讯,复星医药(600196)3月13日公告,近日,公司控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局关于同意FXS0683片用于血液系统恶性肿瘤开展临床试验的批准。复星医药产业拟于条件具备后于中国境内开展FXS0683的I期临床研究。FXS0683为本集团(即本公司及控股子公司/单位)自主研发的口服小分子创新药,为强效及高选择性的新一代Bcl-2抑制剂,拟用于治疗血液系统...
Source Link每经AI快讯,复星医药(600196)3月13日公告,近日,公司控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局关于同意FXS0683片用于血液系统恶性肿瘤开展临床试验的批准。复星医药产业拟于条件具备后于中国境内开展FXS0683的I期临床研究。FXS0683为本集团(即本公司及控股子公司/单位)自主研发的口服小分子创新药,为强效及高选择性的新一代Bcl-2抑制剂,拟用于治疗血液系统...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.